Grant: CIHR Fellowship
Direct Payment
$120,000.00
Genomic prediction of response and resistance to PARP inhibition in breast cancer
EF 2013-14
Résumé
Although new treatments have helped improve the survival of breast cancer patients, the development of new therapies is challenging. Only a small number of therapeutic agents tested in the laboratory have demonstrated efficacy in patients. Laboratory models have commonly used cancer cells alone, but the growth of cancer cells and their response to therapy is affected by their surrounding microenvironment. PARP inhibitors target DNA damage repair mechanisms and are being tested in clinical trials. A better understanding of the mechanism of action of PARP inhibitors and improved laboratory models can help to better select which patients will most benefit from therapy.
My hypothesis is that gene signatures predictive of response and resistance to PARP inhibition can be identified in the laboratory by better understanding the biological pathways and by using a microenvironment model. I will be using cell-spot technology, wherein thousands of growth pads are in one microscope slide, and cellular function is measured with a fluorescent microscope. Several breast cancer cell lines, which are immortalized cancer cells, and various microenvironment proteins will be tested simultaneously. A gene signature, that can predict response and resistance to therapy, will be identified using sophisticated computer programs, and correlated with a gene signature obtained from patients. I will be focusing on a PARP inhibitor that is also being tested in a clinical trial in locally advanced breast cancer patients prior to their surgery, called the I SPY2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis).
In summary, this project strives to identify breast cancer subytpes that will be sensitive and resistant to therapy. There is great potential that the cell-spot technology will be an important pre-clinical tool that will help identify which breast cancer patients will benefit from therapy.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Oregon, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
301439
Name
Hassan Saima N
Region
Oregon
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Genomic prediction of response and resistance to PARP inhibition in breast cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Breast Cancer; Dna Damage Pathways; Integrated Genomic Characterization; Microenvironment Model; Parp Inhibition; Predictive Biomarkers; Therapeutic Response; Therpeutic Resistance
Abstract
Although new treatments have helped improve the survival of breast cancer patients, the development of new therapies is challenging. Only a small number of therapeutic agents tested in the laboratory have demonstrated efficacy in patients. Laboratory models have commonly used cancer cells alone, but the growth of cancer cells and their response to therapy is affected by their surrounding microenvironment. PARP inhibitors target DNA damage repair mechanisms and are being tested in clinical trials. A better understanding of the mechanism of action of PARP inhibitors and improved laboratory models can help to better select which patients will most benefit from therapy.
My hypothesis is that gene signatures predictive of response and resistance to PARP inhibition can be identified in the laboratory by better understanding the biological pathways and by using a microenvironment model. I will be using cell-spot technology, wherein thousands of growth pads are in one microscope slide, and cellular function is measured with a fluorescent microscope. Several breast cancer cell lines, which are immortalized cancer cells, and various microenvironment proteins will be tested simultaneously. A gene signature, that can predict response and resistance to therapy, will be identified using sophisticated computer programs, and correlated with a gene signature obtained from patients. I will be focusing on a PARP inhibitor that is also being tested in a clinical trial in locally advanced breast cancer patients prior to their surgery, called the I SPY2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis).
In summary, this project strives to identify breast cancer subytpes that will be sensitive and resistant to therapy. There is great potential that the cell-spot technology will be an important pre-clinical tool that will help identify which breast cancer patients will benefit from therapy.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Hassan, Saima N
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~